Skip to content

The Clearity Foundation Has Joined OCRA

Together, we’re expanding support, education, and resources for the gynecologic cancer community.

Two women pose for a photo. One rests her head on the other's shoulder. Both are smiling.

Strengthening Support Through Partnership

Ovarian Cancer Research Alliance (OCRA), the world’s leading ovarian and gynecologic cancer nonprofit, is proud to announce that The Clearity Foundation has combined with OCRA. This important development brings together two of the most respected organizations in the ovarian cancer field, combining OCRA’s leading research, advocacy, and patient support programs with Clearity’s focus on scientific education and support for women and families facing an ovarian cancer diagnosis.

 

Please explore the resources below to learn more about the expanded support and tools now available.

For Patients

For Patients

Find essential information here about ovarian cancer prevention, risk factors, and steps to take if you’ve been newly diagnosed, in treatment or navigating life beyond.
Support & Resources

Support & Resources

OCRA is here for you and your family to answer questions or connect you with resources to help you and offer support.
Research

Research

OCRA has awarded more than 400 grants and invested $140 million in ovarian cancer and related gynecologic cancer research initiatives, becoming the largest global charity devoted to ovarian and related gynecologic cancer research in the world.
Center for Public Policy

Center for Public Policy

OCRA advocates on Capitol Hill to improve research and education, drug and diagnostic safety, and access to quality care for all members of the ovarian and gynecologic cancer community, having helped secure $3.8 billion in federal research and education funding since inception..
Get Involved

Get Involved

Help us get one step closer to a cure. There are so many ways to lend a hand and improve the lives of patients and families impacted by ovarian and all gynecologic cancers.
About

About

OCRA is the leading organization in the world fighting ovarian and all gynecologic cancers on all fronts while supporting patients and their families.

Related Topics

OCRA Rivkin Family SummeRun Returns July 12 to Honor a Lasting Legacy and Fund Ovarian Cancer Research

OCRA Rivkin Family SummeRun Returns July 12 to Honor a Lasting Legacy and Fund Ovarian Cancer Research

SEATTLE, WA, July 9, 2026 — Nearly 1,000 runners, walkers, survivors, families, friends, and supporters are expected to gather at Seward Park on Sunday, July 12, for the Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, one of the nation’s longest-running events dedicated to funding ovarian cancer research. Participants of all ages and abilities will transform … Continued

Read more

The Overview: June 2026

The Overview: June 2026

Nearly 500 people have already registered for OCRA’s International Gynecologic Cancer Conference®—the largest conference dedicated to the gynecologic cancer community—taking place on September 16–17. The conference is free, online, and open to all, and will include programming for ovarian, endometrial, cervical, and rare gynecologic cancers. For the first time, each of these diseases will have a dedicated Ask the Experts session. Learn … Continued

Read more

Inside the Think Tank: Stopping Ovarian Cancer Before it Starts

Inside the Think Tank: Stopping Ovarian Cancer Before it Starts

On June 1–2, the Ovarian Cancer Observatory—part of OCRA’s broader investment in research initiatives—convened its first in-person Forum in Vancouver. Roughly 50 of the field’s brightest clinicians, pathologists, and epidemiologists gathered for what became, in essence, a two-day think tank on preventing ovarian cancer.  The Observatory is funded through a grant from OCRA and was … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.